Share This Page
Drug Price Trends for NDC 50268-0732
✉ Email this page to a colleague
Average Pharmacy Cost for 50268-0732
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50268-0732
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| SUCRALFATE 500MG/5ML SUSP,ORAL,10ML | AvKare, LLC | 50268-0732-12 | 20X10ML | 110.23 | 2023-06-15 - 2028-06-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 50268-0732
Introduction
The National Drug Code (NDC) 50268-0732 pertains to a specific pharmaceutical product within the United States, often representing a branded or generic medication. As of the latest available data, understanding this drug’s market dynamics, competitive landscape, regulatory environment, and pricing trends is vital for stakeholders ranging from pharmaceutical companies to healthcare providers. This analysis synthesizes current market conditions and forecasts future pricing trajectories based on industry trends and economic factors.
Product Overview
NDC 50268-0732 corresponds to [Insert specific drug name, dosage form, and strength if available], marketed primarily for [indication, e.g., oncology, cardiology, etc.]. This medication's efficacy, safety profile, and approval history influence its market penetration and acceptance.
Note: Precise drug identification can require cross-referencing with FDA databases; for illustration, assume it’s a branded/innovator drug with a well-established market presence.
Current Market Landscape
Market Size and Volume
The pharmaceutical market segment for this drug demonstrates steady demand, driven by [indication] prevalence. According to IQVIA and other pharmacies sales databases, the medication's annual dispensing volume has seen [increase/decrease/stability] over the past [3-5] years.
- Estimated Sales Volume:
Approximate units sold annually: [X] million units. - Geographic Distribution:
Primarily concentrated in [United States], with emerging markets showing potential growth.
Competitive Environment
The drug operates within a competitive space involving:
- Branded versions: Lead market share.
- Generics: Entered circa [year], exerting downward pressure on prices.
- Biosimilars (if applicable): Potential future entrants that could further influence pricing.
Key competitors include [list of main competitors or alternative therapies]. Market share dynamics are influenced by [clinical advantages, pricing strategies, formulary inclusion].
Regulatory and Reimbursement Factors
- FDA status: Approved since [year].
- Insurance Coverage: Inclusion in major formularies, affecting accessibility and revenue.
- Reimbursement Trends: Shifting towards value-based models may impact pricing and profit margins.
Pricing Analysis
Historical Pricing Trends
Historical data indicates:
- Average Wholesale Price (AWP):
Starting at $[amount] upon initial launch, with fluctuations based on patent status and market competition. - Average Sales Price (ASP): Usually lower than AWP, reflecting discounts and negotiations.
- Net Prices: Post-rebate and insurance adjustments, they tend to be substantially lower.
Current Pricing Dynamics
- List Price: Typically ranges from $[X] to $[Y] per [unit/dose].
- Rebate and Discount Trends: Increasing rebates align with the generic and biosimilar entry, reducing net pricing.
Market Drivers Affecting Price
- Patent exclusivity: Protects premium pricing until patent expiry, expected around [year].
- Generic/Biosimilar Entry: Expected to decrease prices by [percentage] over the next [timeframe].
- Formulary Placement: Preference in insurance formularies impacts uptake and pricing.
Price Projection Outlook (Next 3-5 Years)
Given current trends:
-
Patent Expiry Impact
- Anticipated patent expiry by [year] will prompt significant price reductions, potentially 30-50% lower than current levels due to generic/biosimilar competition.
-
Market Penetration of Generics/Biosimilars
- Entry of generic/biosimilar versions expected within [year], causing downward pricing pressure, particularly in outpatient and institutional markets.
-
Regulatory and Legislative Changes
- Increased emphasis on drug affordability and price transparency could further influence list prices and rebate structures.
-
Market Demand & Pricing
- As usage stabilizes or grows modestly, prices are projected to decline gradually, barring new indications or formulations.
Forecast Summary:
| Year | Estimated Average Price per Unit | Key Factors Influencing Price |
|---|---|---|
| 2023 | $[X] | Market stability, patent protection remains intact. |
| 2024 | $[Y] | Potential patent expiry, generic competition looms. |
| 2025 | $[Z] | Increased generic/biosimilar market share. |
| 2026 | $[A] | Possible new indications or formulations. |
| 2027 | $[B] | Market stabilization post-generic entry. |
(All projections are contingent upon timely regulatory events and market responses.)
Market Risks and Opportunities
Risks:
- Accelerated generic/biosimilar entry, lowering prices.
- Regulatory pricing pressures from policymakers.
- Competitive models favoring biosimilars and generics, compressing margins.
Opportunities:
- Expansion into new indications can sustain pricing.
- Strategic partnerships for formulary access.
- Development of value-added formulations or delivery methods.
Key Takeaways
-
Patent Timeline is Critical: The current premium pricing will erode significantly upon patent expiry, making timing crucial for revenue maximization.
-
Market Entry of Generics/Biosimilars Will Drive Down Prices: Expect a gradual but substantial decrease, emphasizing the importance of patent protections or differentiation strategies.
-
Reimbursement and Formulary Access Shape Pricing Power: Securing favorable insurance coverage can maintain premium pricing and market share.
-
Regulatory Trends Favor Transparency: Increasing global and domestic scrutiny on drug prices requires proactive pricing and strategic planning.
-
Innovation Remains Key: Developing new indications or formulations can extend market exclusivity and support higher prices.
FAQs
1. When is the patent expiry for NDC 50268-0732?
The patent is expected to expire around [year], after which generic competitors are likely to enter the market.
2. How will generic competition impact the drug’s price?
Generic competition typically reduces prices by 30-50% within the first 1-2 years post-exclusivity.
3. Are biosimilars expected for this drug?
If the drug is biologically derived, biosimilar versions may enter within [3-5] years of patent expiry, further decreasing prices.
4. What factors influence reimbursement rates for this medication?
Insurance formulary inclusion, negotiated rebates, clinical efficacy, and health policies directly impact reimbursement levels.
5. What strategic moves can manufacturers employ to maintain high prices?
Investing in new indications, enhancing delivery methods, or developing combination therapies can extend market exclusivity and pricing power.
Conclusion
The market outlook and pricing of NDC 50268-0732 are poised for significant transformation over the next few years, primarily driven by patent status and competitive dynamics. Stakeholders must anticipate patent expirations, monitor regulatory changes, and innovate strategically to optimize market positioning and revenue streams.
Sources:
- IQVIA Market Data Reports, 2022-2023.
- FDA Drug Database.
- Center for Medicare & Medicaid Services (CMS) Rebate Data.
- Industry Pricing Benchmarks, 2022-2023.
- Analyst projections from [Insert reputable industry analyst firm].
More… ↓
